91 results on '"Galetta, D."'
Search Results
2. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1
3. 1019P Pattern of clinical activity of anticancer vaccine OSE2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO) in phase III Atalante-1 randomized trial
4. 1912P AI-based early prediction of radiation pneumonitis in stage III NSCLC patients
5. 1689TiP The social stigma of smokers and patients with lung cancer: Detection of phoenomenon and testing of EMDR (eye movement desensitization and reprocessing) intervention
6. 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database
7. 125P Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data
8. LBA47 Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
9. 2001P Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
10. 2128P exerCise discussion with Oncologist duriNg caNcEr ConsultaTion: The CONNECT study
11. 1510TiP Efficacy study of osimertinib in treatment-naïve patients with EGFR mutant non-small cell lung cancer (NSCLC) according to TP53 mutational status (TEMPLE-2/NCT05785208)
12. 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
13. Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
14. Treatment of advanced non-small cell lung cancer
15. Italian clinical research in non-small-cell lung cancer
16. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials
17. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA–IIIB) non-small-cell lung cancer: long-term results according to downstaging
18. Extrathymic malignancies in patients with thymoma
19. Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial
20. The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
21. Prognostic role of RLF/MYCL1 and circPVT1 in SCLC
22. Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
23. Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
24. Peripheral blood biomarkers as prognostic factors for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
25. Time-series of peripheral blood biomarkers as biomarkers for immunotherapy in advanced non-small cell lung cancer (aNSCLC) patients
26. 55P - Incidence and clinical implications of late immune-related adverse events in long responders to PD-1/PD-L1 checkpoint inhibitors: A multicenter study
27. The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
28. Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial
29. ASTRIS, a real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC): preliminary analysis of the Italian cohort
30. Efficacy of ceritinib administered to patients with crizotinib-refractory, ALK-positive, advanced NSCLC within the Italian compassionate use program
31. Post-survey data about “I do not smoke it”, smoking prevention campaign addressed to schools
32. Italian nivolumab expanded access programme: real-world results in non-squamous non-small cell lung cancer patients
33. 1746P - Prognostic role of RLF/MYCL1 and circPVT1 in SCLC
34. 1588TiP - The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
35. 1568P - Post progression survival for patients treated with docetaxel/nintedanib in the SENECA trial
36. 1518P - Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest
37. 1489PD - Secondary ROS1 mutations and lorlatinib sensitivity in crizotinib-refractory ROS1 positive NSCLC: Results of the prospective PFROST trial
38. Tumor heterogeneity affects the activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in EGFR mutant non-small cell lung cancer (NSCLC) patients (pts)
39. Intercalated combination of chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: A systematic review and meta-analysis
40. Intercalated chemotherapy and epidermal growth factor receptor inhibitors for patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis
41. Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population
42. Chemotherapy-induced nausea and vomiting (CINV) in patients with stage III/IV lung cancer during the first-line treatment: assessment by physician, nurse and patient. Preliminary results from an Italian multicenter survey
43. The role of health professionals in informing patients with pulmonary diseases to stop smoking: final data of an Italian multicentric survey
44. Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study
45. The role of health care professionals in smoking cessation among patients with pulmonary diseases: an Italian multicentric survey
46. Maintenance Therapy (MT) for non-squamous advanced NSCLC: a multicenter Italian survey about patients (pts)' perspectives and physicians' awareness
47. Circulating-free tumor DNA as a surrogate for determination of EGFR status: the Italian experience within the ASSESS study
48. An interdisciplinary early simultaneous palliative approach in metastatic non-small cell lung cancer: preliminary data in outpatient setting
49. P2 - Post-survey data about “I do not smoke it”, smoking prevention campaign addressed to schools
50. E11 - The close link between anxiety and cluster symptoms in lung cancer patients during first-line chemotherapy: further data from a dedicated WALCE (Women Against Lung Cancer in Europe) survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.